Expert consensus of <sup>177</sup>Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

Nuclear Medicine Committee of China Anti-Cancer Association Cancer; Association of Nuclear Medicine Physicians Chinese

doi:10.19401/j.cnki.1007-3639.2024.07.010

您当前的位置：

首页 >

文章列表页 >

Expert consensus of ¹⁷⁷Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

Guideline and Concensus | 更新时间：2025-12-31

- Expert consensus of ¹⁷⁷Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)
- China Oncology Vol. 34, Issue 7, Pages: 702-714(2024)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.07.010
  CLC： R737.25
- Received：19 April 2024，
  
  Revised：2024-06-07，
  
  Published：30 July 2024
- 稿件说明：
移动端阅览
Nuclear Medicine Committee of China Anti-Cancer Association Cancer, Association of Nuclear Medicine Physicians Chinese. Expert consensus of ¹⁷⁷Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)[J]. China Oncology, 2024, 34(7): 702-714.
DOI：

Nuclear Medicine Committee of China Anti-Cancer Association Cancer, Association of Nuclear Medicine Physicians Chinese. Expert consensus of ¹⁷⁷Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)[J]. China Oncology, 2024, 34(7): 702-714. DOI： 10.19401/j.cnki.1007-3639.2024.07.010.

摘要

镥-177标记前列腺特异性膜抗原放射性配体疗法（

177

Lu-labeled prostate-specific membrane antigen radioligand therapy，

177

Lu-PSMA-RLT）是一种通过精准地向前列腺癌细胞递送

177

Lu释放的β射线，引发肿瘤细胞DNA的辐射损伤从而杀灭肿瘤的创新治疗方法。现阶段国内外多个前列腺癌领域权威指南与共识推荐其用于治疗转移性去势抵抗性前列腺癌（metastatic castrate-resistant prostate cancer，mCRPC），国内尚未见关于

177

Lu-PSMA-RLT治疗前列腺癌的临床实践路径和用药规范的报道。本共识由中国抗癌协会肿瘤核医学专业委员会和中国医师协会核医学医师分会共同发起，结合现有的

177

Lu-PSMA-RLT注册研究结果、真实世界数据及国内外放射性核素临床治疗经验，根据牛津循证医学中心临床证据推荐等级和证据级别来评价不同级别的证据，在适应证、患者筛选、用药不良反应、随访和辐射安全等方面给出推荐意见。本共识旨在为临床医师提供

177

Lu-PSMA-RLT治疗前列腺癌的临床参考，为进一步制订行业相关指南奠定基础。

Abstract

177

Lu-labeled prostate-specific membrane antigen radioligand therapy (

177

Lu-PSMA-RLT) is an innovative treatment approach that precisely delivers β radiation emitted by

177

Lu to prostate cancer cells

causing radiation damage to the tumor cells’ DNA and thereby eliminating the tumor. At present

it has been recommended for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) by many international and national authoritative guidelines and consensuses. However

there are no published clinical practice path and medication specifications for diagnosis and treatment in China. Therefore

the consensus was jointly

initiated by Cancer Nuclear Medicine Committee of Chinese Anti-Cancer Association and Chinese Association of Nuclear Medicine Physicians. Physicians from these two committees combined the existing results of

177

Lu-PSMA-RLT registration study

real world data domestic and international clinical experience of radionuclide treatment

and gave recommendations in terms of indications

screening adverse reactions

follow-up and radiation safety by taking different levels of evidence as reference according to clinical evidence levels and grades of recommendation from the Oxford Centre for Evidence-based Medicine. The purpose of this consensus was to provide physicians with reference for clinical application in the practice of

177

Lu-PSMA-RLT for the treatment of prostate cancer based on existing evidence and lay the foundation for the development of subsequent industry-related guidelines.

关键词

Keywords

references

DÖRR M , HÖLZEL D , SCHUBERT-FRITSCHLE G , et al. Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years [J ] . Oncol Res Treat , 2015 , 38 ( 1/2 ): 8 - 14 .

HAN B F , ZHENG R S , ZENG H M , et al. Cancer incidence and mortality in China, 2022 [J ] . J Natl Cancer Cent , 2024 , 4 ( 1 ): 47 - 53 .

中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组 . 前列腺癌筛查中国专家共识(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 5 ): 435 - 440 .

Prostate Cancer Group, the Society of Urogenital and Reproductive System Tumor, China Anti-Cancer Association . China expert consensus on prostate cancer screening (2021 edition) [J ] . China Oncol , 2021 , 31 ( 5 ): 435 - 440 .

樊卫 , 石洪成 . 中国肿瘤整合诊治技术指南(CACA)-2023-核素治疗 [M ] . 天津 : 天津科学技术出版社 , 2023 .

FAN W , SHI H C . Chinese technical guidelines for integrated diagnosis and treatment of cancer (CACA)-2023-nuclide therapy [M ] . Tianjin: Tianjin Science and Technology Press , 2023 .

American Joint Committee on Cancer . AJCC cancer staging manual [M ] . 8th edition. Chicago : Springer , 2018 .

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology prostate cancer version 1. 2024 [EB/OL ] . [ 2024-04-10 ] . https://www.nccn.org/ https://www.nccn.org/ https://www.nccn.org/.

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南. 2023 [M ] . 北京 : 人民卫生出版社 , 2023 .

Chinese Society of Clinical Oncology Guidelines Working Committee . Chinese Society of Clinical Oncology (CSCO) prostate cancer diagnosis and treatment guidelines. 2023 [M ] . Beijing : People’s Medical Publishing House , 2022 .

叶定伟 . 中国肿瘤整合诊治指南(CACA)-2022-前列腺癌 [M ] . 天津 : 天津科学技术出版社 , 2022 : 61 .

YE D W . Chinese technical guidelines for integrated diagnosis and treatment of cancer (CACA)-2022-prostate cancer [M ] . Tianj in: Tianjin Science and Technology Press , 2022 : 61 .

SUN M , NIAZ M J , NIAZ M O , et al. Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer [J ] . Curr Oncol Rep , 2021 , 23 ( 5 ): 59 . DOI: 10.1007/s11912-021-01042-w http://doi.org/10.1007/s11912-021-01042-w

IRAVANI A , VIOLET J , AZAD A , et al. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies [J ] . Prostate Cancer Prostatic Dis , 2020 , 23 ( 1 ): 38 - 52 .

SJÖGREEN GLEISNER K , CHOUIN N , GABINA P M , et al. EANM dosimetry committee recommendations for dosimetry of 177 Lu-labelled somatostatin-receptor- and PSMA-targeting ligands [J ] . Eur J Nucl Med Mol Imaging , 2022 , 49 ( 6 ): 1778 - 1809 .

SANTONI M , SCARPELLI M , MAZZUCCHELLI R , et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises [J ] . J Biol Regul Homeost Agents , 2014 , 28 ( 4 ): 555 - 563 .

SWEAT S D , PACELLI A , MURPHY G P , et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases [J ] . Urology , 1998 , 52 ( 4 ): 637 - 640 . DOI: 10.1016/s0090-4295(98)00278-7 http://doi.org/10.1016/s0090-4295(98)00278-7

AHMADZADEHFAR H , RAHBAR K , BAUM R P , et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with[ 177 Lu ] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) [J ] . Eur J Nucl Med Mol Imaging , 2021 , 48 ( 1 ): 113 - 122 .

RAJASEKARAN A K , ANILKUMAR G , CHRISTIANSEN J J . Is prostate-specific membrane antigen a multifunctional protein? [J ] . Am J Physiol Cell Physiol , 2005 , 288 ( 5 ): C975 -C981.

MANNWEILER S , AMERSDORFER P , TRAJANOSKI S , et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis [J ] . Pathol Oncol Res , 2009 , 15 ( 2 ): 167 - 172 . DOI: 10.1007/s12253-008-9104-2 http://doi.org/10.1007/s12253-008-9104-2

HOFMAN M S , VIOLET J , HICKS R J , et al. [ 177 Lu ] -PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study [J ] . Lancet Oncol , 2018 , 19 ( 6 ): 825 - 833 .

SARTOR O , BONO J D , CHI K N , et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer [J ] . N Engl J Med , 2021 , 385 ( 12 ): 1091 - 1103 .

HOFMAN M S , EMMETT L , SANDHU S , et al. [ 177 Lu ] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial [J ] . Lancet , 2021 , 397 ( 10276 ): 797 - 804 .

SARTOR O , CASTELLANO GAUNA D E , HERRMANN K , et al. LBA13 phase Ⅲ trial of[ 177 Lu ] Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) [J ] . Ann Oncol , 2023 , 34 : S1324 -S1325.

KRATOCHWIL C , FENDLER W P , EIBER M , et al. Joint EANM/SNMMI procedure guideline for the use of 177 Lu-labeled PSMA-targeted radioligand-therapy ( 177 Lu-PSMA-RLT) [J ] . Eur J Nucl Med Mol Imaging , 2023 , 50 ( 9 ): 2830 - 2845 .

HEIDEGGER I , KESCH C , KRETSCHMER A , et al. Biomarkers to personalize treatment with 177 Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review [J ] . Ther Adv Med Oncol , 2022 , 14 : 17588359221081922 .

VIOLET J , JACKSON P , FERDINANDUS J , et al. Dosimetry of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging a nd whole-body tumor dosimetry with treatment outcomes [J ] . J Nucl Med , 2019 , 60 ( 4 ): 517 - 523 .

HOTTA M , GAFITA A , CZERNIN J , et al. Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with 177 Lu-PSMA therapy: a multicenter retrospective analysis [J ] . J Nucl Med , 2022 , 63 ( 10 ): 1484 - 1488 .

GROENER D , NGUYEN C T , BAUMGARTEN J , et al. Hematologic safety of 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer [J ] . EJNMMI Res , 2021 , 11 ( 1 ): 61 .

中华人民共和国生态环境部 . 核医学辐射防护与安全要求:HJ 1188—2021 [S ] . 北京 : 中国环境科学出版社 , 2021 .

Ministry of Ecology and Environment of the People’s Republic of China . Radiation protection and safety requirements for nuclear medicine: HJ 1188—2021 [S ] . Beijing : China Environmental Science Press , 2021 .

中国疾病预防控制中心辐射防护与核安全医学所 , 中国医学科学院放射医学研究所 , 广东省职业病防治院. 核医学放射防护要求:GBZ 120-2020 [S ] . 北京 : 中国标准出版社 , 2020 .

Institute of Radiation Protection and Nuclear Safety Medicine, Chinese Center for Disease Control and Prevention ; Institute of Radiological Medicine, Chinese Academy of Medical Sciences; Guangdong Province Hospital for Occupational Disease Prevention and Treatment. Radiological protection requirements for nuclear medicine: GBZ 120-2020 [S ] . Beijing : Standards Press of China , 2020 .

FAROLFI A , ARMSTRONG W R , DJAILEB L , et al. Differences and common ground in 177 Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers [J ] . J Nucl Med , 2024 , 65 ( 3 ): 438 - 445 .

FENDLER W P , EIBER M , BEHESHTI M , et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 [J ] . Eur J Nucl Med Mol Imaging , 2023 , 50 ( 5 ): 1466 - 1486 .

HUANG S Y , ONG S , MCKENZIE D , et al. Comparison of 18 F-based PSMA radiotracers with[ 68 Ga ] Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis [J ] . Prostate Cancer Prostatic Dis , 2023 . [Online ahead of print ]

RAUSCHER I , KRÖNKE M , KÖNIG M , et al. Matched-pair comparison of 68 Ga-PSMA-11 PET/CT and 18 F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy [J ] . J Nucl Med , 2020 , 61 ( 1 ): 51 - 57 .

European Medicines Agency . Pluvicto: EPAR-product information [EB/OL ] . [ 2024-04-10 ] . https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto.

LADRIÈRE T , FAUDEMER J , LEVIGOUREUX E , et al. Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals [J ] . Pharmaceutics , 2023 , 15 ( 4 ): 1240 .

SCHER H I , MORRIS M J , STADLER W M , et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3 [J ] . J Clin Oncol , 2016 , 34 ( 12 ): 1402 - 1418 . DOI: 10.1200/JCO.2015.64.2702 http://doi.org/10.1200/JCO.2015.64.2702

RAHBAR K , BÖGEMAN M , YORDANOVA A , et al. Delayed response after repeated 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer [J ] . Eur J Nucl Med Mol Imaging , 2018 , 45 ( 2 ): 243 - 246 .

AHMADZADEHFAR H , WEGEN S , YORDANOVA A , et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using[ 177 Lu ] Lu-PSMA-617 [J ] . Eur J Nucl Med Mol Imaging , 2017 , 44 ( 9 ): 1448 - 1454 .

SADAGHIANI M S , SHEIKHBAHAEI S , WERNER R A , et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer [J ] . Eur Urol , 2021 , 80 ( 1 ): 82 - 94 . DOI: 10.1016/j.eururo.2021.03.004 http://doi.org/10.1016/j.eururo.2021.03.004

CHI K N , ARMSTRONG A J , KRAUSE B J , et al. Safety analyses of the phase 3 VISION trial of[ 177 Lu ] Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer [J ] . Eur Urol , 2024 , 85 ( 4 ): 382 - 391 .

SPITZ A , FLOYD R , SUTTON J , et al. Practical guidance on[ 177 Lu ] Lu-PSMA-617 treatment, including radiation safety, adverse event monitoring, and patient counseling [J ] . Clin J Oncol Nurs , 2023 , 27 ( 5 ): 539 - 547 .

MICHALSKI K , KLEIN C , BRUEGGEMANN T , et al. Assessing response to[ 177 Lu ] PSMA radioligand therapy using modified PSMA PET progression criteria [J ] . J Nucl Med , 2021 , 62 ( 12 ): 1741 - 1746 .

麻广宇 , 巴建涛 , 彭程 , 等 . 177 Lu-DOTATATE治疗神经内分泌瘤患者对环境辐射安全的研究进展 [J ] . 同位素 , 2022 , 35 ( 2 ): 128 - 134 .

MA G Y , BA J T , PENG C , et al. Research progress of 177 Lu-DOTATATE in the treatment of neuroendocrine tumor patients with environmental radiation safety [J ] . J Isot , 2022 , 35 ( 2 ): 128 - 134 .

DEMIR M , ABUQBEITAH M , USLU-BEŞLI L , et al. Evaluation of radiation safety in (177) Lu-PSMA therapy and development of outpatient treatment protocol [J ] . J Radiol Prot , 2016 , 36 ( 2 ): 269 - 278 .

MORGANTETTI G , NG K L , SAMARATUNGA H , et al. Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis [J ] . Transl Androl Urol , 2019 , 8 ( Suppl 2 ): S147 -S155.

MAHAJAN S , GREWAL R K , FRIEDMAN K P , et al. Assessment of salivary gland function after 177 Lu-PSMA radioligand therapy: current concepts in imaging and management [J ] . Transl Oncol , 2022 , 21 : 101445 .

KULKARNI H R , SINGH A , SCHUCHARDT C , et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience since 2013 [J ] . J Nucl Med , 2016 , 57 ( Suppl 3 ): 97 S- 104 S.

HERRMANN K , RAHBAR K , EIBER M , et al. Renal and multiorgan safety of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy [J ] . J Nucl Med , 2024 , 65 ( 1 ): 71 - 78 .

KRATOCHWIL C , FENDLER W P , EIBER M , et al. EANM procedure guidelines for radionuclide therapy with 177 Lu-labelled PSMA-ligands ( 177 Lu-PSMA-RLT) [J ] . Eur J Nucl Med Mol Imaging , 2019 , 46 ( 12 ): 2536 - 2544 .

邓颖 , 何丽萌 , 孙占良 , 等 . 177 Lu-PSMA-617治疗前列腺癌对公众人群外照射辐射剂量研究 [J ] . 中华核医学与分子影像杂志 , 2022 , 42 ( 9 ): 529 - 533 .

DENG Y , HE L M , SUN Z L , et al. Study on external radiation dose of 177 Lu-PSMA-617 in treatment of prostate cancer in public population [J ] . Chin J Nucl Med Mol Imaging , 2022 , 42 ( 9 ): 529 - 533 .

LI H , LIU G B , CHEN S G , et al. Radiation levels of patients with metastatic castration-resistant prostate cancer treated with 177 Lu-PSMA-617 [R ] . Washington : American College of Rheumatology , 2024 .

HOPE T A , ABBOTT A , COLUCCI K , et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177 Lu-DOTATATE [J ] . J Nucl Med , 2019 , 60 ( 7 ): 937 - 943 .

OLMSTEAD C , CRUZ K , STODILKA R , et al. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol [J ] . Nucl Med Commun , 2015 , 36 ( 2 ): 129 - 134 . DOI: 10.1097/MNM.0000000000000232 http://doi.org/10.1097/MNM.0000000000000232

LEVART D , KALOGIANNI E , CORCORAN B , et al. Radiation precautions for inpatient and outpatient 177 Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours [J ] . EJNMMI Phys , 2019 , 6 ( 1 ): 7 .

CALAIS P J , TURNER J H . Radiation safety of outpatient 177 Lu-octreotate radiopeptide therapy of neuroendocrine tumors [J ] . Ann Nucl Med , 2014 , 28 ( 6 ): 531 - 539 .

KENDI A T , HALFDANARSON T R , PACKARD A , et al. Therapy with 177 Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors [J ] . AJR Am J Roentgenol , 2019 , 213 ( 2 ): 309 - 317 .

Pluvicto ® 1 000 MBq/mL solution for injection/infusion [M ] . 2023 .

RASUL S , HACKER M , KRETSCHMER-CHOTT E , et al. Clinical outcome of standardized 177 Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7 400 MBq every 4 weeks [J ] . Eur J Nucl Med Mol Imaging , 2020 , 47 ( 3 ): 713 - 720 .

RATHKE H , GIESEL F L , FLECHSIG P , et al. Repeated 177 Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq [J ] . J Nucl Med , 2018 , 59 ( 3 ): 459 - 465 .

EMMETT L , JOHN N , PATHMANANDAVEL S , et al. Patient outcomes following a response biomarker-guided approach to treatment using 177 Lu-PSMA-I & T in men with metastatic castrate-resistant prostate cancer (Re-SPECT) [J ] . Ther Adv Med Oncol , 2023 , 15 : 17588359231156392 .

MADER N , SCHOELER C , PEZESHKPOUR N , et al. Intermittent radioligand therapy with 177 Lu-PSMA-617 for oligometastatic castration-resistant prostate cancer [J ] . Cancers , 2023 , 15 ( 18 ): 4605 .

PETERS S M B , PRIVÉ B M , BAKKER M D , et al. Intra-therapeutic dosimetry of[ 177 Lu ] Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome [J ] . Eur J Nucl Med Mol Imaging , 2022 , 49 ( 2 ): 460 - 469 .

EAPEN R S , BUTEAU J P , JACKSON P , et al. Administering[ 177 Lu ] Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1/2 study [J ] . Eur Urol , 2024 , 85 ( 3 ): 217 - 226 .

KOSTOS L , BUTEAU J P , YEUNG T , et al. AlphaBet: Combination of Radium-223 and[ 177 Lu ] Lu-PSMA-I & T in men with metastatic castration-resistant prostate cancer (clinical trial protocol) [J ] . Front Med , 2022 , 9 : 1059122 .

EMMETT L , SUBRAMANIAM S , JOSHUA A M , et al. ENZA-p trial protocol: a randomized phase Ⅱ trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) [J ] . BJU Int , 2021 , 128 ( 5 ): 642 - 651 .

PATELL K , KURIAN M , GARCIA J A , et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review [J ] . Expert Rev Anticancer Ther , 2023 , 23 ( 7 ): 731 - 744 .

SATHEKGE M , BRUCHERTSEIFER F , KNOESEN O , et al. 225 Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study [J ] . Eur J Nucl Med Mol Imaging , 2019 , 46 ( 1 ): 129 - 138 .

FEUERECKER B , TAUBER R , KNORR K , et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA [J ] . Eur Urol , 2021 , 79 ( 3 ): 343 - 350 . DOI: 10.1016/j.eururo.2020.11.013 http://doi.org/10.1016/j.eururo.2020.11.013

LAWAL I O , MORGENSTERN A , VORSTER M , et al. Hematologic toxicity profile and efficacy of[ 225 Ac ] Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer [J ] . Eur J Nucl Med Mol Imaging , 2022 , 49 ( 10 ): 3581 - 3592 .

SATHEKGE M , BRUCHERTSEIFER F , VORSTER M , et al. mCRPC patients receiving 225 Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: response to treatment and survival analysis [J ] . J Nucl Med , 2022 , 63 ( 10 ): 1496 - 1502 .

Views

4164

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Chinese expert consensus on perioperative integrated rehabilitation for radical prostatectomy (2024 edition)

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Expert consensus on diagnosis and treatment of hematologic malignancies with solid tumors (2025 version)

The research on construction of the spontaneous prostate tumor and breast cancer model of Pten^fl/fl;Trp53^fl/fl;Pbsn-iCre⁺ transgenic mouse

Related Author

of Integrated Rehabilitation for Urogenital Tumors Committee

Anti-Cancer Association Chinese

Hao LIU

Junjie SU

Shiyong XIN

Ye GUO

Chaosu HU

Chenping ZHANG

Related Institution

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology

Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

College of Life Sciences, Inner Mongolia University, Hohhot 010000, Inner Mongolia Autonomous Region

AI问答

⁰

Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

DOI：10.19401/j.cnki.1007-3639.2024.07.010

摘要

Abstract

关键词

Keywords

references

Expert consensus of ¹⁷⁷Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)